Latest updates demonstrate commitment to customers and market leadership of Phoenix Platform
PRINCETON, N.J.— June 12, 2023. Certara®, the global leader in biosimulation, today announced the launch of version 8.4 of its Phoenix™ platform, the industry gold standard in pharmacokinetic/ pharmacodynamic (PK/PD) and toxicokinetic modeling and simulation software. Version 8.4 delivers new features driven by customer demand that improve efficiency, quality, and speed.
Key Phoenix 8.4 updates include the following:
- Usability Enhancements: Scientists will find a number of improvements focused on making Phoenix more intuitive and streamlined. For example, duplicating objects within a workflow is a convenience that will save time and allow PK experts to work more effectively.
- Auditability Improvements: Certara understands the importance of maintaining a robust audit trail. One of the auditability features in Phoenix 8.4 is the ability to easily set user preference for UTC or system time zone for date/time formatting.
- Compatibility Upgrades: The release makes Phoenix more compatible than ever before. For example, Phoenix 8.4 now supports more data filetypes, including sas7bdat files and SAS transport file (XPT) formats through v9.
These enhancements extend to various aspects of the software, including the Phoenix Platform, Reporting, Charting, and NLME. The updates are expected to significantly enhance the Phoenix user’s ability to analyze, interpret, and visualize data.
About Phoenix
The Phoenix platform is used worldwide by more than 6,000 scientists at biopharmaceutical companies, academic and non-profit institutions, and regulatory agencies. Eleven regulatory agencies, including the U.S. FDA, PMDA in Japan, and NMPA in China, rely on Phoenix to evaluate life-saving drug candidates.
For more information on the Phoenix platform, please https://www.certara.com/software/phoenix-pkpd/.
About Certara
http://www.certara.com/ Certara accelerates medicines using proprietary biosimulation software, technology and services to transform traditional drug discovery and development. Its clients include more than 2,000 biopharmaceutical companies, academic institutions, and regulatory agencies across 62 countries.